SIREN : 341853554
BIO WEST is a French company founded 38 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in NUAILLE (49340), this company of category PME shows in 2024 a revenue of 20.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20 740 877 € | 21 742 041 € | 24 935 360 € | 17 567 551 € | 19 627 048 € | 19 882 411 € | 12 911 266 € | 21 889 195 € |
| Net income | 893 307 € | 2 798 710 € | 2 197 352 € | 1 103 560 € | 1 738 459 € | 2 153 586 € | 1 278 485 € | 2 913 765 € |
| EBITDA | 2 532 723 € | 3 798 915 € | 5 302 886 € | 2 384 464 € | 3 381 610 € | 3 527 248 € | 2 319 708 € | 4 873 700 € |
| Net margin | 4.3% | 12.9% | 8.8% | 6.3% | 8.9% | 10.8% | 9.9% | 13.3% |
In 2024, BIO WEST achieves revenue of 20.7 M€. Activity remains stable over the period (CAGR: -0.8%). Slight decline of -5% vs 2023. After deducting consumption (15.0 M€), gross margin stands at 5.8 M€, i.e. a rate of 28%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.5 M€, representing 12.2% of revenue. Warning negative scissor effect: despite revenue change (-5%), EBITDA varies by -33%, reducing margin by 5.3 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 893 k€, i.e. 4.3% of revenue. This profit can be retained or distributed to shareholders.
20 740 877 €
5 763 488 €
2 532 723 €
2 021 517 €
893 307 €
12.2%
The debt ratio (= Financial debt / Equity x 100) stands at 14%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 71%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 11.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
14.284%
71.486%
11.235%
1.474
45.6%
In 2024, the debt ratio of BIO WEST (14.28) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIO WEST (71.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of BIO WEST (1.47) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 519.82. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.5x. Operating income very largely covers interest expenses: high safety margin.
519.819
7.5
In 2024, the liquidity ratio of BIO WEST (519.82) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIO WEST (7.5x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 46 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 125 days. Excellent situation: suppliers finance 79 days of the operating cycle (retail model). Inventory turnover is 435 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 441 days of revenue, i.e. 25.4 M€ to permanently finance. Over 2017-2024, WCR increased by +82%, requiring additional financing.
25 399 900 €
46 j
125 j
435 j
441 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 178 231€ to 547 815€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIO WEST with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of BIO WEST in 2024 is 20.7 M€.
Yes, BIO WEST generated a net profit of 893 k€ in 2024.
The headquarters of BIO WEST is located in NUAILLE (49340), in the department Maine-et-Loire.
The tax return of BIO WEST is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIO WEST operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.